Mild cognitive impairment (MCI) leading to Alzheimer's disease and related disorders (ADRD) represents a significant health and economic burden of the rapidly expanding senior population. The accurate detection and diagnosis of MCI and its common comorbidity, late-life depression (LLD), is essential for prolonging patient quality of life and developing advancements in research and treatment options. The purpose of the proposed program is to refine Miro Health's A.I. to accurately detect, differentiate and diagnose MCI and LLD.
Study Type
OBSERVATIONAL
Enrollment
960
Miro Health
Sacramento, California, United States
RECRUITINGMiro Health
Miami, Florida, United States
RECRUITINGMeasure usability of Miro Health assessments (iOS and Android) for patients
Measure the (a) time point 1 in-assessment drop-out rate; and (b) the rate of lost-to-time-point-2-followup at 12 months.
Time frame: Year 1, Q3 - Year 2, Q2
Measure acceptability of Miro Health assessments (iOS and Android) for patients
Measure the participant preference for pencil-paper test or Miro Health Mobile Assessment
Time frame: Year 1, Q3 - Year 2, Q2
Measure domain score correlations of pencil-paper tests and Miro Health Mobile Assessment
Pairwise correlations greater than 0.8 and statistically significantly greater than 0.7 will be considered successful.
Time frame: Year 1, Q1 - Year 2, Q2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.